Special Issue "Biomarkers for Predicting Treatment Response and Guiding Therapy in COVID-19 Patients"
Deadline for manuscript submissions: 31 December 2021.
Interests: neuro-immune interactions; neurodegeneration; CSF biomarkers; vitamin D; biomarkers; laboratory medicine; clinical chemistry
Special Issues and Collections in MDPI journals
With the SARS-CoV-2 outbreak, an unprecedented amount of literature data regarding the biological and clinical aspects of COVID-19 has been published, and papers addressing the role of biomarkers in COVID-19 are no exception. However, it is questionable whether this trendy wave has contributed to scientific progress. Indeed, almost any analyte can change during a severe infection like COVID-19 and correlate with disease severity and survival, but no biomarker can impact clinical practice until it has been proven to help clinicians guiding treatment. Although several studies have documented the association between COVID-19 severity and circulating levels of C-reactive protein (CRP), IL-6, prothrombin (PT), and D-dimer, the clinical usefulness of these biomarkers in COVID-19 is far from being proven, also because many studies were affected by several drawbacks, weakening the strength of their results (i.e., retrospective design, discrepancies in the assay methods used, in the cut-off used, in the time point of measurement, in the endpoints chosen). Additionally, data on treatment response are few and limited to CRP and IL-6. A recent IFCC recommendation encourages using caution before translating study results on biomarkers in COVID-19 patients into laboratory–clinical practice, especially when the use of cut-offs is proposed. Hence, reliable data from rigorous studies are needed to clarify whether and which biomarkers can be used to manage SARS-CoV-2-infected patients.
This Special Issue aims to collect novel, homogeneous data on biomarkers of treatment response in COVID-19 patients. Research and review articles attempting to prove how and which biomarkers can help clinicians to predict treatment response are highly encouraged.
Prof. Dr. Giulia Bivona
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Predictive value
- Treatment response
- C-reactive protein